IL145600A0 - Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins - Google Patents

Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins

Info

Publication number
IL145600A0
IL145600A0 IL14560000A IL14560000A IL145600A0 IL 145600 A0 IL145600 A0 IL 145600A0 IL 14560000 A IL14560000 A IL 14560000A IL 14560000 A IL14560000 A IL 14560000A IL 145600 A0 IL145600 A0 IL 145600A0
Authority
IL
Israel
Prior art keywords
pro
inhibitors
maduraphthalazine
derivatives
inflammatory cytokins
Prior art date
Application number
IL14560000A
Other languages
English (en)
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of IL145600A0 publication Critical patent/IL145600A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14560000A 1999-04-17 2000-04-11 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins IL145600A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917505A DE19917505A1 (de) 1999-04-17 1999-04-17 Verwendung von Maduraphthalazin-Derivaten als Inhibitoren proinflammatorischer Cytokine
PCT/EP2000/003182 WO2000063181A1 (de) 1999-04-17 2000-04-11 Verwendung von maduraphthalazin-derivaten als inhibitoren proinflammatorischer cytokine

Publications (1)

Publication Number Publication Date
IL145600A0 true IL145600A0 (en) 2002-06-30

Family

ID=7904992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14560000A IL145600A0 (en) 1999-04-17 2000-04-11 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins

Country Status (24)

Country Link
US (1) US6440968B1 (de)
EP (1) EP1171425A1 (de)
JP (1) JP2002542232A (de)
KR (1) KR20010108515A (de)
CN (1) CN1347408A (de)
AU (1) AU4546100A (de)
BG (1) BG106009A (de)
BR (1) BR0009821A (de)
CA (1) CA2305893A1 (de)
CZ (1) CZ20013712A3 (de)
DE (1) DE19917505A1 (de)
EA (1) EA200101096A1 (de)
EE (1) EE200100537A (de)
HK (1) HK1039932A1 (de)
HU (1) HUP0200783A3 (de)
IL (1) IL145600A0 (de)
IS (1) IS6093A (de)
MX (1) MXPA01010050A (de)
NO (1) NO20015033L (de)
SK (1) SK14812001A3 (de)
TR (1) TR200102984T2 (de)
WO (1) WO2000063181A1 (de)
YU (1) YU72601A (de)
ZA (1) ZA200107886B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210535D0 (en) * 2002-05-08 2002-06-19 Novartis Ag Organic compounds
EP2095823A1 (de) * 2002-07-30 2009-09-02 Stem Cell Therapeutics Inc. Oligodendrozytenherstellung aus multipotenten neuralen Stammzellen
US20070042978A1 (en) * 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
US20080096947A1 (en) * 2004-10-15 2008-04-24 Heidelberg Pharma Ag Parenteral Forms Of Administration Of Imexon And Method For The Production Thereof
ATE421956T1 (de) * 2006-09-19 2009-02-15 Leibniz Inst Naturstoff Forsch Antibiotikum maduraphthalazin-salze mit verzögerter wirkstofffreigabe des wirkstoffs und deren verwendung
CN109310147B (zh) 2016-07-11 2021-08-31 菲利普莫里斯生产公司 疏水性胶囊，用于制造胶囊的方法和含有胶囊的吸烟制品
EP3898610B1 (de) * 2018-12-21 2022-10-19 Fondazione Istituto Insubrico di Ricerca per la Vita Neuartige antibiotische aza-hexapen-verbindungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE7706C (de) * Dr. G. H. E. BERING in Bromberg Verfahren zur Entbitterung von Lupinen mit Hülfe kohlensaurer Alkalien
DE19719522A1 (de) * 1996-08-17 1998-02-19 Gruenenthal Gmbh Neue polycyclische Phthalazinderivate, Verfahren zu Ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
JP2002542232A (ja) 2002-12-10
EP1171425A1 (de) 2002-01-16
MXPA01010050A (es) 2002-04-24
BR0009821A (pt) 2002-01-15
NO20015033D0 (no) 2001-10-16
HUP0200783A2 (hu) 2002-11-28
CZ20013712A3 (cs) 2002-03-13
CA2305893A1 (en) 2000-10-17
KR20010108515A (ko) 2001-12-07
IS6093A (is) 2001-09-28
EA200101096A1 (ru) 2002-04-25
WO2000063181A1 (de) 2000-10-26
BG106009A (en) 2002-06-28
TR200102984T2 (tr) 2002-03-21
US6440968B1 (en) 2002-08-27
SK14812001A3 (sk) 2002-05-09
NO20015033L (no) 2001-11-21
AU4546100A (en) 2000-11-02
ZA200107886B (en) 2004-03-29
DE19917505A1 (de) 2000-10-19
EE200100537A (et) 2002-12-16
CN1347408A (zh) 2002-05-01
YU72601A (sh) 2004-05-12
HUP0200783A3 (en) 2002-12-28
HK1039932A1 (zh) 2002-05-17

Similar Documents

Publication Publication Date Title
AU3546601A (en) Pyrimidine-4-one derivatives as LDL-PLA<sub>2</sub> inhibitors
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
HUP0202450A3 (en) N-heterocyclic derivatives as nos inhibitors
AU4458700A (en) Uses of phenylglycine derivatives
GB9911417D0 (en) Furanone derivatives as inhibitors of cathepsin s
PL352296A1 (en) Crystalline derivatives of 1-methylocarbapeneme
EP1219600A4 (de) Prostaglandin-derivate
HK1047276A1 (zh) 作為pde4抑制劑的四氫噻喃2，3-二氮雜萘酮類衍生物
PL355021A1 (en) Isoxazole derivatives to be used as phosphodiesterase vii inhibitors
AU2001292122A1 (en) Heterocyclic derivatives useful as pharmaceutical agents
IL145600A0 (en) Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins
PL355020A1 (en) Imidazole derivatives as phosphodiesterase vii inhibitors
AU1817700A (en) 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
EP1157617B1 (de) Verwendung von alpha-Ketoenaminderivaten als kühlende Mittel
GB0215275D0 (en) Benzo(a)phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II
EP1170286A4 (de) Prostaglandin e1 derivate
AU4917000A (en) Oligohydroxyl substituted benzofuran-3-yl and pyridofuranylurea derivatives as phosphodiesterase iv inhibitors
AU4021700A (en) Methods of use of beta1-integrin inhibitors
HK1053059A1 (zh) 新用途
AU2002340038A1 (en) Method for the selective removal of acyl-functionality attached to the 2'-hydroxy-group of paclitaxel-related derivatives
AU6002700A (en) Heterocyclic derivatives as inhibitors of factor xa
HU9904011D0 (en) Novel salts of dipeptid derivatives